<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Analysis using the public microarray database Gene Expression Omnibus indicates significantly higher <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of VEGF and VEGFRs in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and high grade <z:hpo ids='HP_0009592'>astrocytoma</z:hpo> but not in <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
<SENT sid="1" pm="."><plain>Human malignant <z:hpo ids='HP_0009592'>astrocytoma</z:hpo> cell lines (U251-MG and U373-MG) and HT-1080 <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo> cells expressed relatively higher levels of VEGF and VEGFRs compared to hepatocellular and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of exogenous VEGF-A induced cell growth in a dose-dependent fashion in <z:hpo ids='HP_0009592'>astrocytoma</z:hpo> and <z:hpo ids='HP_0100244'>fibrosarcoma</z:hpo> cells but not in colorectal and hepatocellular <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>The blockade of VEGF inhibited cell survival only in U251-MG, U373-MG and HT-1080 cells </plain></SENT>
<SENT sid="4" pm="."><plain>These results collectively suggest the role of autocrine VEGF signaling in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and provide a basis for the variable clinical responses to antiangiogenic therapy observed in different types of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>